{"eventGroups":[{"description":"CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0.\n\nGRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96.","id":"EG000","otherNumAffected":12,"otherNumAtRisk":12,"seriousNumAffected":3,"seriousNumAtRisk":12,"title":"Arm I (Nonmyeloablative Regimen)"},{"description":"CONDITIONING: Patients are assigned to 1 of 2 treatment groups.\n\nGroup A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2.\n\nGroup B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4.\n\nTRANSPLANTATION: Patients undergo PBSC infusion on day 0.\n\nGRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11.","id":"EG001","otherNumAffected":11,"otherNumAtRisk":11,"seriousNumAffected":4,"seriousNumAtRisk":11,"title":"Arm II (Myeloablative Regimen)"}],"frequencyThreshold":"5","otherEvents":[{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12,"numEvents":0},{"groupId":"EG001","numAffected":6,"numAtRisk":11,"numEvents":6}],"term":"Mucositis"},{"organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":12,"numEvents":12},{"groupId":"EG001","numAffected":5,"numAtRisk":11,"numEvents":5}],"term":"Infection"}],"seriousEvents":[{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12,"numEvents":2},{"groupId":"EG001","numAffected":2,"numAtRisk":11,"numEvents":2}],"term":"severe diarrhea due to gut GVHD"},{"organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":11,"numEvents":0}],"term":"tachycardia and hypotenstion"},{"organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Thrombotic Microangiopathy"},{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Mucositis"}]}